Patent · US Active

CD40L-specific TN3-derived scaffolds and methods of use thereof

US10000553B2 · kind B2 · utility

4Cited by

0References

19Claims

0Family size

Assignee

Viela Bio, Inc. · US

Inventors

Anthony Coyle · Washington, US
Manuel Baca · Gaithersburg, US
Thomas Thisted · New Market, US
Stacey Drabic · Gaithersburg, US
Luba Grinberg · Gaithersburg, US
Shabazz Novarra · Gaithersburg, US
Vaheh Oganesyan · Gaithersburg, US
Ronald Herbst · Gaithersburg, US
David Kenneth Spencer · Gaithersburg, US

Key dates

Filing date	Oct 10, 2012
Grant date	Jun 19, 2018
Priority date	—
Expiry date	Dec 15, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.